How have TRIB shares performed in 2023?

Trinity Biotech's stock was trading at $0.99 at the start of the year. Since then, TRIB shares have decreased by 55.7% and is now trading at $0.4382. View the best growth stocks for 2023 here .

Are investors shorting Trinity Biotech?

Trinity Biotech saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 59,700 shares, an increase of 70.1% from the October 31st total of 35,100 shares. Based on an average daily volume of 27,600 shares, the short-interest ratio is presently 2.2 days. View Trinity Biotech's Short Interest .

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) released its quarterly earnings results on Tuesday, October, 3rd. The company reported ($0.20) EPS for the quarter. The business earned $13.90 million during the quarter. Trinity Biotech had a negative net margin of 46.51% and a negative trailing twelve-month return on equity of 870.11%.

What guidance has Trinity Biotech issued on next quarter's earnings?

Trinity Biotech issued an update on its third quarter 2023 earnings guidance on Tuesday, October, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.00 million-$15.00 million, compared to the consensus revenue estimate of $15.00 million.

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?

20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com . Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD) , Novavax (NVAX) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Advanced Micro Devices (AMD) , Netflix (NFLX) , Pfizer (PFE) , QUALCOMM (QCOM) , Energy Transfer (ET) and Exxon Mobil (XOM) .

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Trinity Biotech?

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Trinity Biotech Stock Price, News & Analysis (NASDAQ:TRIB)

$0.44

+0.00 (+1.09%)

(As of 02:08 PM ET)

Compare

Today's Range: $0.42
▼
$0.45
50-Day Range: $0.39
▼
$0.74
52-Week Range: $0.37
▼
$1.37

Volume: 83,731 shs
Average Volume: 41,015 shs
Market Capitalization: $16.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Trinity Biotech MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.16% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.59) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.11 out of 5 stars

Medical Sector

928th out of 949 stocks

Diagnostic Substances Industry

14th out of 14 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Trinity Biotech.

3.0

Short Interest

Percentage of Shares Shorted
0.16% of the outstanding shares of Trinity Biotech have been sold short.
Short Interest Ratio / Days to Cover
Trinity Biotech has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Trinity Biotech has recently increased by 70.09%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Trinity Biotech does not currently pay a dividend.
Dividend Growth
Trinity Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRIB.

2.4

News and Social Media Coverage

News Sentiment
Trinity Biotech has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Trinity Biotech this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for TRIB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added Trinity Biotech to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trinity Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Trinity Biotech is held by insiders.
Percentage Held by Institutions
Only 16.28% of the stock of Trinity Biotech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Trinity Biotech are expected to grow in the coming year, from ($0.59) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trinity Biotech is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trinity Biotech is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Trinity Biotech Stock (NASDAQ:TRIB)

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

TRIB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRIB Stock News Headlines

November 28, 2023 | finance.yahoo.com

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

November 24, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 22, 2023 | msn.com

Oil Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

November 6, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

November 3, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Up 2.5%

October 23, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

October 10, 2023 | finance.yahoo.com

Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

October 5, 2023 | finance.yahoo.com

Trinity Biotech plc (NASDAQ:TRIB) Q2 2023 Earnings Call Transcript

October 5, 2023 | finance.yahoo.com

Trinity Biotech plc (NASDAQ:TRIB) Just Reported Earnings, And Analysts Cut Their Target Price

October 3, 2023 | finanznachrichten.de

Trinity Biotech plc: Trinity Biotech Announces Q2 2023 Financial Results

October 3, 2023 | finance.yahoo.com

Trinity Biotech Announces Q2 2023 Financial Results

September 28, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Lower After Positive Start in Wednesday Trading

September 27, 2023 | finance.yahoo.com

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results

September 21, 2023 | msn.com

The biotech CEO trying to reverse aging has removed all but 3 things from his bedroom

September 12, 2023 | finanznachrichten.de

Trinity Biotech plc: Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

September 11, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Open Week Higher Monday

September 8, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher Friday

September 1, 2023 | finance.yahoo.com

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

August 28, 2023 | finance.yahoo.com

Trinity Biotech PLC (TRIB): A Comprehensive Analysis of Its Market Value

August 25, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Decline Friday, Set to End Week 1% Lower

August 24, 2023 | msn.com

Pharmaceutical Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower Thursday

August 18, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Lower Friday

August 15, 2023 | benzinga.com

Trinity Packaging Supply Named to Inc. Magazine's Fastest-Growing Companies 2023

August 8, 2023 | msn.com

Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Slightly Higher Tuesday

August 7, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Kick Off Week on Strong Note

See More Headlines

Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/03/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TRIB
CUSIP: N/A
CIK: 888721
Web: www.trinitybiotech.com
Phone: (531) 276-9800
Fax: 353-1276-9888
Employees: 398
Year Founded: 1992

Profitability

EPS (Most Recent Fiscal Year): ($0.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,010,000.00
Net Margins: -46.51%
Pretax Margin: -64.52%
Return on Equity: -870.11%
Return on Assets: -31.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.59
Quick Ratio: 2.06

Sales & Book Value

Annual Sales: $74.78 million
Price / Sales: 0.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.06) per share
Price / Book: -7.30

Miscellaneous

Outstanding Shares: 38,110,000
Free Float: 34,983,000
Market Cap: $16.70 million
Optionable: Optionable
Beta: 1.44

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Aris Kekedjian (Age 56)
CEO & Chairman
Comp: $387k
Mr. Ronan O'Caoimh (Age 67)
Founder & Director
Comp: $340k
Mr. John Gillard (Age 42)
CFO, Company Secretary & Executive Director
Comp: $863k
Dr. James Walsh Ph.D. (Age 65)
Executive Director of Business Development & Executive Director
Comp: $20k
Mr. Simon Dunne (Age 49)
Chief Accounting Officer
Dr. Gary Keating Ph.D. (Age 50)
Chief Technology Officer
Ms. Eibhlin Kelly (Age 39)
Chief Information Officer
Mr. Colm Molloy (Age 52)
Group Director of Human Resources & Culture

Key Competitors

View All Competitors

TRIB Stock Analysis - Frequently Asked Questions

How have TRIB shares performed in 2023?: Trinity Biotech's stock was trading at $0.99 at the start of the year. Since then, TRIB shares have decreased by 55.7% and is now trading at $0.4382.
View the best growth stocks for 2023 here.
Are investors shorting Trinity Biotech?: Trinity Biotech saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 59,700 shares, an increase of 70.1% from the October 31st total of 35,100 shares. Based on an average daily volume of 27,600 shares, the short-interest ratio is presently 2.2 days.
View Trinity Biotech's Short Interest.
How were Trinity Biotech's earnings last quarter?: Trinity Biotech plc (NASDAQ:TRIB) released its quarterly earnings results on Tuesday, October, 3rd. The company reported ($0.20) EPS for the quarter. The business earned $13.90 million during the quarter. Trinity Biotech had a negative net margin of 46.51% and a negative trailing twelve-month return on equity of 870.11%.
What guidance has Trinity Biotech issued on next quarter's earnings?: Trinity Biotech issued an update on its third quarter 2023 earnings guidance on Tuesday, October, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.00 million-$15.00 million, compared to the consensus revenue estimate of $15.00 million.

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?: 20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Trinity Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).
Who are Trinity Biotech's major shareholders?: Trinity Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Trinity Biotech?: Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TRIB) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial